No Recurrence of VTE 1 Year after COVID-19-Associated VTE Event
A study was conducted to determine outcomes in hospitalized patients with COVID-19 and VTE, during anticoagulation therapy and at 1-year follow-up.
A study was conducted to determine outcomes in hospitalized patients with COVID-19 and VTE, during anticoagulation therapy and at 1-year follow-up.
Researchers examined the effect of anticoagulation therapy in patients with atrial fibrillation on risk for severe thrombotic events and severe hemorrhage events.
Researchers sought to determine whether thromboprophylaxis would reduce venous thromboembolism risk in patients with SCD and a central venous access device.
Investigators compared outcomes of thrombolytic therapy and surgery as first-line treatment for patients with obstructive prosthetic valve thrombosis.
A study was conducted to determine clinical outcomes for patients who received CYP2C19-guided antiplatelet therapy after percutaneous coronary intervention.
A study assessed the association between postprocedural anticoagulation therapy and multiple clinical outcomes in patients with STEMI.
The USPSTF evaluated the harms and benefits of screening for atrial fibrillation in adults without history of stroke.
A study was conducted to determine the efficacy and safety of genotype-guided dosing strategies for patients receiving warfarin.
The updated CHEST guideline on antithrombotic therapy for VTE includes 4 new PICO questions as well as updated recommendations based on newer evidence.
In a multinational cohort study, researchers compared the clinical outcomes of patients selected for mechanical thrombectomy by noncontrast CT vs those selected by CTP or MRI in the extended time window.